Management of RA medications in pregnant patients
Authors:
- Monika ØstensenMØMonika Østensen
- Frauke FörgerFFFrauke Förger
- 9 June 2009
- journal article
- review article
- Published by Springer Nature in Nature Reviews Rheumatology
- Vol. 5 (7) , 382-390
Abstract
A desire for children or the presence of pregnancy limits the drug therapy options for a woman with rheumatoid arthritis. Combination therapies that include methotrexate or new drugs that have not been studied or used in pregnant patients must be excluded, even though they might be highly efficacious. With few exceptions, the reason for this exclusion is not the proven teratogenicity of the drugs, but the absence of proven safety for the fetus. Whereas methotrexate, leflunomide, abatacept and rituximab must be withdrawn before a planned pregnancy, tumor necrosis factor inhibitors and bisphosphonates can be continued until conception. Antimalarial agents, sulfasalazine, azathioprine and ciclosporin are compatible with pregnancy, and so can be administered until birth. Corticosteroids and analgesics such as paracetamol (acetaminophen) can also be used throughout pregnancy. NSAIDs can be safely administered until gestational week 32. The most important consideration when managing rheumatoid arthritis medications during pregnancy is that therapy must be tailored for the individual patient according to disease activity.Keywords
This publication has 75 references indexed in Scilit:
- Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysisAnnals of the Rheumatic Diseases, 2009
- Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E InitiativeAnnals of the Rheumatic Diseases, 2009
- A Safety Assessment of Tumor Necrosis Factor Antagonists During Pregnancy: A Review of the Food and Drug Administration DatabaseThe Journal of Rheumatology, 2009
- Rituximab Administration in Third Trimester of Pregnancy Suppresses Neonatal B-Cell DevelopmentJournal of Immunology Research, 2008
- Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)- therapyRheumatology, 2006
- Pregnancy outcome in women who were exposed to anti–tumor necrosis factor agents: Results from a national population registerArthritis & Rheumatism, 2006
- Outcome of Pregnancy in Women Receiving Infliximab for the Treatment of Crohn's Disease and Rheumatoid ArthritisAmerican Journal of Gastroenterology, 2004
- Maternal use of acetaminophen and nonsteroidal anti‐inflammatory drugs (NSAIDs), and muscular ventricular septal defectsBirth Defects Research Part A: Clinical and Molecular Teratology, 2004
- No effects of bisphosphonates on the human fetusBirth Defects Research Part A: Clinical and Molecular Teratology, 2003
- Transplacental effects of bisphosphonates on fetal skeletal ossification and mineralization in ratsTeratology, 1999